ApoCell, Inc.
Precision for Medicine is dedicated to supporting and advancing clinical development to bring innovative therapies to patients efficiently. They leverage integrated infrastructure, scientific expertise, and a collaborative approach to reduce delays and costs in bringing new treatments to market. As part of the Precision Medicine Group, they specialize in oncology, rare diseases, autoimmune conditions, infectious diseases, and diagnostics, offering services across all stages of clinical development, including CRO, laboratory, biospecimen, and data intelligence services. Their mission emphasizes patient-focused care, innovation, operational excellence, and a commitment to community service and industry leadership.
Industries
Nr. of Employees
Very Large (1000+)
ApoCell, Inc.
Frederick, Maryland, United States, North America
Patents
CXCR3 as epigenetic marker for the identification of inflammatory immune cells, in particular CD8+ memory t cells
US-12305237-B2
View DetailsEpigenetic method to detect and distinguish IPEX and IPEX-like syndromes, in particular in newborns
US-12247258-B2
View DetailsMethod for epigenetic immune cell detection and counting in human blood samples
US-12006546-B2
View DetailsERGIC1 as epigenetic marker for the identification of immune cells, in particular monocytic myeloid-derived suppressor cells (mMDSCs)
US-11976327-B2
View DetailsMVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells
US-11788141-B2
View Details
CXCR3 as epigenetic marker for the identification of inflammatory immune cells, in particular CD8+ memory t cells
US-12305237-B2
View DetailsEpigenetic method to detect and distinguish IPEX and IPEX-like syndromes, in particular in newborns
US-12247258-B2
View DetailsMethod for epigenetic immune cell detection and counting in human blood samples
US-12006546-B2
View DetailsERGIC1 as epigenetic marker for the identification of immune cells, in particular monocytic myeloid-derived suppressor cells (mMDSCs)
US-11976327-B2
View DetailsMVD as epigenetic marker for the identification of immune cells, in particular CD56+ NK cells
US-11788141-B2
View DetailsServices
Comprehensive CRO services including study design support, project management, site network access, patient recruitment, decentralized trials, monitoring, and medical monitoring.
Central laboratory and specialty testing services providing sample processing, PBMC services, immunology and biomarker assays, bioanalysis, pathology-based tissue analytics and digital pathology.
Access to FFPE blocks/slides, fresh/frozen tissues, tissue microarrays, H&E images and annotated clinical metadata from a large tissue biorepository; custom prospective collections and pathologist verification available.
Provision of NGS‑characterized biospecimen sets (tumor/normal/adjacent) with DNA/RNA, variant characterization data and image datasets to support biomarker discovery and diagnostic development.
Customizable liquid biopsy collections including cfDNA, circulating tumor cells and NGS‑characterized plasma; options for specialty tubes, matched biopsies and direct shipping to specialty labs for processing.
In‑house pathology review, IHC and automated multiplex immunofluorescence staining, microdissection and slide scanning services with rapid turnarounds for tissue characterization.
Comprehensive CRO services including study design support, project management, site network access, patient recruitment, decentralized trials, monitoring, and medical monitoring.
Central laboratory and specialty testing services providing sample processing, PBMC services, immunology and biomarker assays, bioanalysis, pathology-based tissue analytics and digital pathology.
Access to FFPE blocks/slides, fresh/frozen tissues, tissue microarrays, H&E images and annotated clinical metadata from a large tissue biorepository; custom prospective collections and pathologist verification available.
Provision of NGS‑characterized biospecimen sets (tumor/normal/adjacent) with DNA/RNA, variant characterization data and image datasets to support biomarker discovery and diagnostic development.
Customizable liquid biopsy collections including cfDNA, circulating tumor cells and NGS‑characterized plasma; options for specialty tubes, matched biopsies and direct shipping to specialty labs for processing.
In‑house pathology review, IHC and automated multiplex immunofluorescence staining, microdissection and slide scanning services with rapid turnarounds for tissue characterization.
Expertise Areas
- Clinical trial management and operations
- Central and specialty laboratory services
- Biospecimen procurement, tissue biorepository and custom collections
- NGS-characterized biospecimens and molecular characterization
Key Technologies
- Next-generation sequencing (NGS) — RNA‑seq, WES and targeted panels
- Single-cell sequencing
- Droplet digital PCR (ddPCR) and quantitative PCR (qPCR)
- Multi-parameter and spectral flow cytometry
News & Updates
Recognition for operational excellence and innovative solutions in oncology and rare disease research, including a successful rescue of a high-risk hematology-oncology trial.
A detailed case study highlighting the company's ability to conduct complex cell therapy research globally with zero sample loss.
An article explaining modern adaptive strategies in phase 1 clinical trial designs.
An article discussing the CRM approach in phase I clinical trials.
An article discussing the BLRM approach in phase I clinical trials.
Awarded for innovative solutions in drug development, especially in complex oncology and rare disease trials.
Recognition for operational excellence and innovative solutions in oncology and rare disease research, including a successful rescue of a high-risk hematology-oncology trial.
A detailed case study highlighting the company's ability to conduct complex cell therapy research globally with zero sample loss.
An article explaining modern adaptive strategies in phase 1 clinical trial designs.
An article discussing the CRM approach in phase I clinical trials.
An article discussing the BLRM approach in phase I clinical trials.
Awarded for innovative solutions in drug development, especially in complex oncology and rare disease trials.